Hengrui Medicine (Jiangsu) Net Worth is5810.0 $Million
VN:F [1.9.22_1171]
deserves the money?
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Would you date ?
Rating: 0.0/5 (0 votes cast)
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
Apatinib was first synthesized by Advenchen Laboratories in California, USA and is being developed by Jiangsu Hengrui Medicine (China), LSK BioPartners (US) and Bukwang Pharmaceutical Company (Korea). It is an investigational cancer drug currently undergoing clinical trials as a potential targeted treatment for metastatic gastric carcinoma, metastatic breast cancer and advanced hepatocellular carcinoma.
The principal investigator from Fudan University, China, presented results of Phase I/II human clinical studies at the 2009 CSCO Meeting (October 17, 2009). Cancer patients were administered varied doses of Apatinib daily for 28 days. Apatinib was well tolerated at doses below 750 mg/day, 3 of 3 dose limiting toxicities were reported at 1000 mg/day and the maximum tolerated dose is determined to be 850 mg/day. The investigator also reported of 65 cancer patients treated in Phase I/II, 1.54% had a complete response, 12.31% had a partial response, 66.15% had stable disease and 20% had progressive disease.
A separate published report on the safety and pharmacokinetics of apatinib in Human clinical studies concludes that it has encouraging antitumor activity across a broad range of cancer types.
There is a Phase II/III study recruiting patients in China to determine whether apatinib can improve progression free survival compared with placebo in patients with metastatic gastric carcinoma who have failed two lines of chemotherapy (September, 2009).
As of November, 2010, two a

(Visited 6 times, 1 visits today)

Hengrui Medicine (Jiangsu) Latest News

Chinese pharma giant invests in NJ startup

a joint venture between Jiangsu Hengrui Medicine Co Ltd (JHM) and an undisclosed US investment firm, on a $100 million investment in HTI. The proceeds from the investment will be used to advance clinical trials in Hengrui Therapeutics' pharmaceutical ...
Posted: June 27, 2016, 4:31 pm

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y

* Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million) Source text in Chinese: http://bit.ly/2xP9Bnd Further company coverage: ($1 = 6.6219 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)
Posted: October 18, 2017, 3:28 am

BRIEF-Jiangsu Hengrui Medicine in licensing agreement with Japan's Oncolys Biopharma

* Says it signs licensing agreement with Japan’s Oncolys Biopharma on medicine telomelysin’s sales in China, Hong Kong and Macau
Posted: December 1, 2016, 4:00 pm
Related Topics:
Hengrui Medicine (Jiangsu), Hengrui Medicine (Jiangsu) Age, Hengrui Medicine (Jiangsu) Bio, Hengrui Medicine (Jiangsu) Country, Hengrui Medicine (Jiangsu) Date Of Birth, Hengrui Medicine (Jiangsu) Earnings, Hengrui Medicine (Jiangsu) Ethnicity, Hengrui Medicine (Jiangsu) Gossips, Hengrui Medicine (Jiangsu) Height, Hengrui Medicine (Jiangsu) History, Hengrui Medicine (Jiangsu) Home Town, Hengrui Medicine (Jiangsu) Images, Hengrui Medicine (Jiangsu) Income, Hengrui Medicine (Jiangsu) Job, Hengrui Medicine (Jiangsu) Nationality, Hengrui Medicine (Jiangsu) Net Worth, Hengrui Medicine (Jiangsu) Networth, Hengrui Medicine (Jiangsu) News, Hengrui Medicine (Jiangsu) Partner, Hengrui Medicine (Jiangsu) Place Of Birth, Hengrui Medicine (Jiangsu) Rumors, Hengrui Medicine (Jiangsu) Salary, Hengrui Medicine (Jiangsu) Secrets, Hengrui Medicine (Jiangsu) Videos, Hengrui Medicine (Jiangsu) Weight, How Much Is Hengrui Medicine (Jiangsu) Earnings, How Much Is Hengrui Medicine (Jiangsu) Income, How Much Is Hengrui Medicine (Jiangsu) Net Worth, How Much Is Hengrui Medicine (Jiangsu) Salary, How Much Is Hengrui Medicine (Jiangsu) Worth, Jiangsu Hengrui Medicine, Jiangsu Hengrui Medicine Address, Jiangsu Hengrui Medicine Annual Report, Jiangsu Hengrui Medicine C-o, Jiangsu Hengrui Medicine Co, Jiangsu Hengrui Medicine Co Ltd Annual Report, Jiangsu Hengrui Medicine Co Ltd China, Jiangsu Hengrui Medicine Co Ltd Contact, Jiangsu Hengrui Medicine Co. Ltd, Jiangsu Hengrui Medicine Company, Jiangsu Hengrui Medicine Company Ltd, Jiangsu Hengrui Medicine Company Ltd. (bf), Jiangsu Hengrui Medicine Contact, Jiangsu Hengrui Medicine Diabetes, Jiangsu Hengrui Medicine Email, Jiangsu Hengrui Medicine Ltd, Jiangsu Hengrui Medicine Pipeline, Jiangsu Hengrui Medicine Reuters, Who Is Hengrui Medicine (Jiangsu),